3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Stomach Neoplasms
2
Solid Tumor
2
Meningioma
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Recurrence
1
Non-small Cell Lung Cancer Metastatic
1
Neurofibromatosis 2
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Sunitinib
64
Nivolumab
54
Sorafenib
38
Bevacizumab
35
Axitinib
35
pembrolizumab
34
Everolimus
30
cabozantinib
29
pazopanib
26
aldesleukin
26
Ipilimumab
23
Interleukin-2
19
Specimen Handling
17
Magnetic Resonance Spectroscopy
17
Gemcitabine
17
lenvatinib
16
Interferon-alpha
15
Interferon alpha-2
13
Radiosurgery
12
Cyclophosphamide
12
fludarabine phosphate
11
atezolizumab
10
durvalumab
8
Introns
8
Erlotinib Hydrochloride
8
Biopsy
8
temsirolimus
7
avelumab
7
Radiotherapy
7
Capecitabine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Renal Cell
×
vistusertib
×
Clear all
NCT01793636
2014-06-24
ZEBRA
Queen Mary University of London
Phase 2
Terminated
49 enrolled